Matthew Kadnar Talks About His Transition From Law to Finance

Episode Summary

Executive Summary: The conversation with GMO’s Matt Kadner centers on valuation-driven, benchmark-free asset allocation, the firm’s long-standing mean-reversion framework, and why GMO remains cautious on U.S. stocks and nominal bonds. Kadner explains GMO’s shift from law to investing, the rationale behind seven-year forecasts, concerns about financial repression, inflation, and liquidity, and why EM value and select non-U.S. markets look most attractive today.

Main Topics: Kadner’s career pivot from law to finance (Priority: 4/5): Kadner describes leaving litigation because he disliked the adversarial, high-stress environment and found finance better matched his communication and sales strengths. GMO’s asset-allocation philosophy and seven-year forecasts (Priority: 5/5): The discussion explains GMO’s long-term forecasting process, built on valuation, growth, and income, and why the firm uses a seven-year horizon based on bubble-cycle history. Benchmark-free investing and the 'where to hide' portfolio (Priority: 5/5): Kadner details GMO’s move away from benchmark constraints toward a portfolio designed to maximize real returns by owning assets that are cheap, not index-compliant. Outlook for U.S. equities, bonds, and inflation risk (Priority: 5/5): Kadner argues U.S. stocks and nominal bonds are expensive, expected returns are weak, and rising inflation or higher rates could compress valuations materially. Global relative value: EM value, EFA value, and opportunity sets (Priority: 4/5): He says emerging-market value is the clearest attractive opportunity, with EFA value next, while U.S. equities remain least attractive on valuation. Market structure, liquidity, and passive indexing (Priority: 4/5): The conversation explores how ETFs, mutual funds, and indexing affect liquidity, price discovery, and potentially increase fragility in stressed credit markets. Behavioral discipline, bubbles, and humility (Priority: 3/5): Kadner emphasizes GMO’s self-scrutiny, the difficulty of being early, and the need to avoid becoming complacent after prior bubble calls.

Key Arguments: Kadner moved from law to finance because litigation made him miserable, while finance fit his strengths in communication and relationship-building. GMO’s approach is grounded in valuation and mean reversion, not short-term market timing; starting price largely determines long-run outcomes. The firm’s seven-year forecast horizon was chosen because historical bubbles averaged about six and a half years from rise to fall. Benchmark constraints can force investors to own expensive assets and underweight cheap ones, reducing long-term compounding. U.S. equities are expensive by almost every valuation metric, with expected seven-year real returns negative under GMO’s normal assumptions. Nominal bonds have very limited upside after decades of falling yields; GMO prefers TIPS and real duration as inflation protection. Financial repression and easy monetary policy have pushed investors into risk assets, but quantitative tightening and rate normalization may reverse that support. High yield and leveraged-loan markets pose liquidity risk because mutual funds and ETFs offer daily liquidity on inherently illiquid assets. Emerging-market value is the cheapest major opportunity set and has become GMO’s largest relative bet among equities. Passive indexing may increase inefficiencies and create more opportunities for active managers who can find mispriced stocks. Rising inflation is a major risk because it can raise discount rates, compress multiples, and harm both equity and bond portfolios.

Data Points: GMO assets under management: about $70 billion - Kadner cites GMO’s approximate firm size during the discussion. Kadner tenure at GMO: almost 15 years - He joined GMO in 2004 and says he has been there nearly 15 years. Seven-year forecast horizon origins: 6.5 years average - Ben Inker’s study of 28 historical bubbles found the average rise-and-fall period was six and a half years, leading GMO to adopt a seven-year forecast. Traditional institutional spending rate: 5% - Kadner explains why ‘five real’ matters for endowments and foundations that typically spend about 5% of assets. U.S. large-cap forecast after 2009 bottom: close to 9% a year - He notes GMO’s forecast for U.S. large stocks near the 2009 market bottom was around 9% annualized. Subsequent U.S. large-cap return: over 12% annualized - Actual returns over the next seven years exceeded GMO’s bullish bottom-of-cycle forecast. Current U.S. large-cap forecast under normal mean reversion: minus 4.9 real a year for seven years - Kadner says GMO’s hot-off-the-press forecast for U.S. large caps is deeply negative in real terms. Alternative 'hell' scenario for U.S. large caps: minus 2 real - Under zero-real cash assumptions, GMO’s forecast improves but remains negative. Value portfolio performance metric: Sharpe ratio over 1 - Kadner says GMO’s benchmark-free 'where to hide' portfolio has compounded at a Sharpe ratio above one. U.S. equity outperformance versus EM: 100 points vs. the rest of the world; 150 points vs. EM - He describes the magnitude of U.S. relative outperformance during the recent cycle. Market drawdown mentioned: 11% - Kadner notes the February selloff fell about 11%, which still rattled investors. Hedge fund industry size: over 11,000 funds - He says the hedge fund universe has grown dramatically from around 1,000 in 2000. Hedge fund attrition: about 25% disappear each year - Kadner describes how many hedge funds shut down and restart, often without resetting high-water marks.

Pivotal Quotes: "If you enjoy what you're doing, you'll never work a day in your life." — Matt Kadner: He recounts the advice that helped him leave law and move into finance. "Liquid claims on illiquid investments." — Barry Ritholtz: This phrase is used in discussing the liquidity risk of mutual funds and ETFs in high-yield and leveraged-loan markets. "Our mantra with clients has been own as little U.S. equities as your committee or your career will allow." — Matt Kadner: He summarizes GMO’s current stance on U.S. equity exposure given valuation concerns.

Implications: Listeners should expect GMO to remain cautious on U.S. stocks and nominal bonds, favor real assets and non-U.S. value, and watch inflation, rates, and liquidity as the biggest regime-change risks for portfolios.